Corcept Therapeutics Incorporated

CORT · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders11.5%

Institutions77.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$761.41M	$675.04M	$482.38M	$401.86M	$365.98M	$353.87M	$306.49M	$251.25M	$159.20M	$81.32M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$12.98M	$10.88M	$6.48M	$5.38M	$5.28M	$5.58M	$5.50M	$5.21M	$3.55M	$2.06M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$44.80M	$136.95M	$107.28M	$112.63M	$124.48M	$128.20M	$111.61M	$89.50M	$52.85M	$10.18M
Operating income as a percentage of revenue.	5.9%	20.3%	22.2%	28.0%	34.0%	36.2%	36.4%	35.6%	33.2%	12.5%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$99.65M	$141.21M	$106.14M	$101.42M	$112.51M	$106.01M	$94.18M	$75.41M	$129.12M	$8.14M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.95	$1.35	$1.02	$0.95	$0.97	$0.92	$0.82	$0.00	$1.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.82	$1.23	$0.94	$0.87	$0.89	$0.85	$0.77	$0.00	$1.00	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$120.50M	$127.67M	$135.55M	$66.33M	$77.62M	$76.19M	$31.27M	$41.63M	$31.06M	$51.54M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$836.65M	$840.55M	$621.52M	$583.43M	$423.76M	$571.73M	$412.31M	$311.69M	$220.54M	$68.75M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	–	–	$0	$14.66M
Everything the company owes — debt, unpaid bills, and other obligations.	$188.85M	$160.96M	$114.81M	$81.59M	$47.95M	$48.39M	$41.13M	$35.81M	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$647.80M	$679.59M	$506.70M	$501.84M	$375.81M	$523.34M	$371.18M	$275.88M	$190.97M	$41.38M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$142.00M	$198.07M	$127.04M	$120.32M	$167.89M	$151.97M	$136.12M	$115.67M	$60.94M	$18.39M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$211000	$2.17M	$139000	$413000	$469000	$1.24M	$1.09M	$298000	$419000	$194000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$141.78M	$195.90M	$126.90M	$119.91M	$167.42M	$150.73M	$135.03M	$115.37M	$60.52M	$18.20M

	You	Peer avg
P/E	248.0	23.4
Revenue Growth	+31.7%	+7.9%
ROE	8.2%	18.3%

Corcept Therapeutics Incorporated

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison